Instructions for Budesonide Easyhaler (Budesonide) powder 200 doses
English Product Name
Budesonide Easyhaler
Dosage form
powder d/ingal. metered dose 200 μg/1 dose: inhaler 200 doses
Description
Powder for inhalation is metered white or almost white, homogeneous, without non-degradable agglomerates.
1 dose
Budesonide 200 mcg
Excipients: lactose monohydrate - 7.8 mg.
2.5 g (200 doses) - polymer metered-dose inhalers (1) - bags of aluminum laminated foil (1) - cardboard packs.
ATX Codes
R03BA02 Budesonide
Clinical and pharmacological groups / Group affiliation
GCS for topical use
Active ingredient
Budesonide
Pharmaco-therapeutic group
Glucocorticosteroid for topical use
Testimony Budesonide Easyhaler:
- Treatment of bronchial asthma (as a basic therapy;
- with insufficient effectiveness of beta2-adrenomimetics;
- to reduce the dose of oral corticosteroids);
- treatment of COPD;
- stenosing laryngotracheitis (false croup).
Dosage, Course and Dosage Budesonide Izhekhayler:
Budenite Steri-Neb is used inhalation using nebulizer inhalers (see below - "Technique of use").
Recommended doses of the drug in case of initiation of inhaled GCS therapy in severe bronchial asthma, as well as against the background of dose reduction or discontinuation of oral corticosteroids for adults (including the elderly) and children over 12 years of age - one to two mg twice / day, maintenance dose - 0.5-4 mg / day; for children from 6 months to twelve years - 0.25-0.5 mg twice a day, maintenance dose - 0.25-two mg per day. In the event that the recommended dose does not exceed one mg per day, the entire dose of the drug can be taken at a time (at a time).
Use in children
Contraindicated in children under the age of 6 months. Use in older children is possible in dosage forms intended for this category of patients.
- Nosology (ICD codes)
- J05.0
- Acute obstructive laryngitis [croup]
- J44
- Another chronic obstructive pulmonary disease
- J45
- Asthma
pharmachologic effect:
GCS with a pronounced local anti-inflammatory and antiallergic effect. Budesonide increases the production of lipocortin, which is an inhibitor of phospholipase A2, inhibits the release of arachidonic acid, inhibits the synthesis of leukotrienes and prostaglandins, reduces inflammatory exudation and cytokine production, inhibits the migration of macrophages, reduces the severity of infiltration and granulation processes, the formation of the substance chemotaxis (which explains the effectiveness in delayed hypersensitivity reactions), inhibits the release of mediators from mast cells inflammation (immediate hypersensitivity reaction).
